Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Drug Innovation And Production Program To Focus On Ten Diseases

This article was originally published in PharmAsia News

Executive Summary

At the 2009 International Conference for Bioeconomy in Tianjin, Sang Guowei, chief technology director for China's new drug innovation and production program, talked about progress in the program. Three objectives have been set: (1) developing new drugs with effectiveness, safety and low price; (2) cultivating specialized talent in the Yangtze River Delta, Pearl River Delta and Bohai Bay Rim to set up a healthcare system which conforms to China's conditions; and (3) speeding up TCM modernization. To meet the healthcare reform requirements, especially to align with those of rural medical cooperatives, the project will allocate 43 percent of its total research funds to fight 10 major diseases, including malignant tumors, cerebral and cardiac vascular diseases, diabetes, mental disorders, immunological diseases, AIDS, drug-resistant tuberculosis, drug-resistant tumors and viral diseases. (Click here for more - Chinese Language)

You may also be interested in...

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts